
KPTI
Karyopharm Therapeutics Inc
Biotechnology
Karyopharm Therapeutics Inc (KPTI) Stock News
The latest KPTI headlines and market coverage — 1 recent story, updated throughout the day.
- GlobeNewswire Inc.·
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc. - KPTI
Pomerantz LLP is investigating potential securities fraud claims against Karyopharm Therapeutics following the company's disclosure of a retention program offering executives cash awards ranging from $625,000 to $1,725,000. The announcement triggered a significant stock price decline of 21.45% on July 20, 2026, closing at $7.47 per share.